PHARMACOLOGY OF AQUEOUS OUTFLOW IN THE EYE

说明(调查人员摘要)：建议的总体目标 研究是为了进一步了解黄连的生理学和药理学 在拟议的研究中，研究人员 已经选择了两大类用于治疗的药物 青光眼的治疗；肾上腺素能药和胆碱能药。这个 具体目标是描述流出设施对这些药物的反应 在她最近描述的人类孤立流出通路灌流模型中， 绘制流出组织中药物受体的分布图，并 描述相关的第二信使系统。这三管齐下 方法，协调生理、生物化学和分子方面的研究 生物学，有可能产生更丰富的信息 而不是每一种单独的方法的总和。最近的改进 在分子生物学技术及其应用方面正在发生革命性的变化 疾病的诊断和治疗，以及基础医学研究。 调查人员希望她的方法，利用这一强大的新技术 结合人类TM模型的技术将使她能够开发 一张人类流出系统的合成地图，它将定位 调节流出阻力变化的细胞，并表征 与这些变化相关联的第二信使系统。增强版 理解正常流出的基本机制(S) 生理学可能为原发性开角型青光眼的发病机制提供新的视角 青光眼，并可能会促进更有效的发展， 特效、安全的抗青光眼药物。

DESCRIPTION (Investigator's Abstract): The overall goal of proposed research is to gain further knowledge of the physiology and pharmacology of aqueous outflow in the human eye.In proposed studies, the investigators have chosen to look at two general classes of drugs used therapeutically in the treatment of glaucoma; adrenergic agents and cholinergic agents. The specific aims are to characterize outflow facility responses to these drugs in her recently described human isolated outflow pathway perfusion model, to map the distribution of drug receptors in outflow tissues, and to characterize relevant second messenger systems. This three-pronged approach, coordinating studies in physiology, biochemistry, and molecular biology, has the potential for producing a wealth of information greater than the sum of each individual approach in isolation. Recent refinements in molecular biology techniques and their applications is revolutionizing the diagnosis and treatment of disease, as well as basic medical research. The investigator's hope that her approach, using this powerful new technology in conjunction with the human TM model will allow her to develop a composite map of the human outflow system which will localize groups of cells which mediate changes in outflow resistance and characterize the second messenger systems which are coupled to these changes. Enhanced understanding of the basic mechanism(s) underlying normal outflow physiology may lend new insight into the pathogenesis of primary open angle glaucoma, and probably will facilitate the development of more effective, specific, and safe antiglaucoma drugs.